|Videos|August 24, 2022
Patient Selection for Atopic Dermatitis Therapies
Elizabeth A. Swanson, MD, provide insight on identifying the appropriate patients for various therapeutic regimens in atopic dermatitis.
Advertisement
Episodes in this series
Advertisement
Related to this article
AHA, AAP, ACOG, and SMFM issued a Female Life Stage framework that starts cardiovascular risk assessment at perimenarche, around ages 8 to 15.
In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.
A four-dose 25-valent PCV series elicited responses to all 25 serotypes in infants, with serotype 3 GMCs ~15-fold higher than PCV20 after dose 4.
Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.
Adding emotion skills to family-based weight treatment didn't boost teen weight loss but cut regain and emotional eating 12 months later.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
4 societies tie girls' and women's heart health to female life stages
2
25-valent pneumococcal vaccine hits all serotypes in infant trial
3
Zilurgisertib reduces HO volume in children aged 6 to 11 with FOP
4
FDA proposes cadmium action levels for baby food under Closer to Zero
5